AMOEBA (EPA:ALMIB) - AMOEBA : ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON 27 MAY 2021 - MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

Transparency directive : regulatory news

10/05/2021 17:35

PRESS RELEASE

Chassieu, 10 may 2021

     ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON 27 MAY 2021
   MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

The company's shareholders are invited to attend the ordinary and extraordinary
general meeting which will be held on:

                          Thursday 27 may 2021 - 9 am
     at the company registered office - 38 Avenue des Frères Montgolfier -
                                69680 CHASSIEU

The notice of the meeting, including the agenda and the planned resolutions,
was published in the BALO (Bulletin of obligatory legal announcements) of April
21, 2021; the notice convening the meeting was published in the BALO of May 10,
2021.

The documents stipulated by article R.225-83 of the French commercial code are
available to shareholders from the moment that the assembly is convened, in
line with the applicable regulatory requirements:

* Any registered shareholder can, until the fifth day (inclusive) before the
assembly, ask the company to send him these documents. For holders of bearer
shares, this right can only be exercised upon presentation of a statement of
participation in the accounts of bearer shares held by the authorised
intermediary;

* Any shareholder can consult these documents at the company's headquarters
during the 15 days preceding the date of the meeting.

For information, electronic voting via the VOTACCESS secure voting platform for
the General Meeting of Thursday, May 27, 2021 will be open from May 10, 2021
until Wednesday, May 26, 2021 at 3:00 pm (Paris time). Shareholders wishing to
use this platform can consult the access conditions in the notice of meeting
and on the company's website
(https://amoeba-nature.com/investisseur/assemblee-generale).

Disclaimer

In the context of the coronavirus epidemic (COVID-19) , the procedures for
holding the Shareholders' Meeting may change depending on health and/or legal
requirements. Shareholders are invited to regularly consult the section
dedicated to the Shareholders' Meeting on the Company's website
(http://www.amoeba-nature.com/Investors/General-assembly).

The results of the votes on resolutions will be posted on the Company's
website.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 341 109,20 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA : ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD ON 27 MAY 2021 - MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE

Transparency directive : regulatory news

AMOEBA's latest news

Other stories